Dr VK Paul, member NITI Aayog, busts myths on India's vaccination process

New Delhi [India], May 27 : Chair of the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and Member (Health) in NiTi Aayog, Dr Vinod K Paul on Thursday addressed seven myths on India's Covid-19 vaccination program.
In an official release, NiTi Aayog said these myths are arising due to distorted statements, half-truths, and blatant lies.
Myth 1: Centre is not doing enough to buy vaccines from abroad
Busting the myth, Dr Paul said the Central government has remained engaged continuously with all the major international vaccine manufacturers right from mid-2020.
"Multiple rounds of discussions have happened with Pfizer, Johnson and Johnson and Moderna. The government offered all assistance to have them supply and manufacture their vaccines in India. However, it is not that their vaccines are available in free supply. We need to understand that buying vaccines internationally is not similar to buying 'off the shelf' items," he said.
The NiTi Aayog member further said the vaccines are in limited supply globally, and companies have their own priorities, game plans, and compulsions in allocating finite stocks.
"They also give preference to countries of their origin just as our own vaccine makers have done unhesitatingly for us. As soon as Pfizer indicated vaccine availability, Central Government and the company are working together for the earliest possible import of the vaccine. As a result of the Government of India's (GoI) efforts, Sputnik vaccine trials got accelerated and with timely approval, Russia has already sent two tranches of vaccines and accomplished tech-transfer to our companies that would start manufacturing very soon. We reiterate our request to all international vaccine makers to come and make in India - for India and for the world," he added.

Myth 2: Centre has not approved vaccines available globally
Contrary to the myth, Dr Paul informed the Central government has proactively eased the entry of vaccines approved by US FDA, EMA, the UK's MHRA and Japan's PMDA, and WHO's Emergency Use Listing into India in April.
"These vaccines will not need to undergo prior bridging trials. The provision has now been further amended to waive off the trial requirement altogether for the well-established vaccines manufactured in other countries. No application of any foreign manufacturer for approval is pending with the drugs controller," he said.
Myth 3: Centre is not doing enough to ramp up domestic production of vaccines
Listing the facts, the NiTi Aayog member said the Central Government is playing the role of an effective facilitator to enable more companies to produce vaccines from early 2020.
"There is only 1 Indian company (Bharat Biotech) that has the IP (intellectual property). GoI has ensured that three other companies/plants will start production of Covaxin apart from enhancing Bharat Biotech's own plants, which have increased from one to four. Covaxin production by Bharat Biotech is being increased from under 1 Cr per month to 10 Cr month by October. Additionally, the three PSUs will together aim to produce up to 4.0 Cr doses by December," he said.
Dr Paul informed that with the constant encouragement of the government, Serum Institute is ramping up Covishield production of 6.5 crore doses per month to 11.0 crore doses per month, and GoI is also ensuring in partnership with Russia that Sputnik will be manufactured by 6 companies coordinated by Dr Reddy's.
"The Union Government is supporting efforts of Zydus Cadila, BioE as well Gennova for their respective indigenous vaccines through liberal funding under Covid Suraksha scheme as also the technical support at national laboratories. The development of Bharat Biotech's single-dose intranasal vaccine is proceeding well with GoI funding, and it could be a game-changer for the world. The estimate of production of over 200 crore doses by our vaccine industry by the end of 2021 is the result of such efforts and unstinted support and partnership. How many countries can even dream of such an enormous capacity, and that too across conventional as well as cutting-edge DNA and mRNA platforms? GoI and vaccine manufacturers have worked as one Team India in this mission with seamless engagement on daily basis," he added.

Myth 4: Centre should invoke compulsory licensing
NEGVAC chair said the Compulsory Licensing is not a very attractive option since it is not a 'formula' that matters, but an active partnership, training of human resources, sourcing of raw materials, and highest levels of bio-safety labs which are required.
"Tech transfer is the key and that remains in the hands of the company that has carried out research and development. In fact, we have gone one step ahead of Compulsory Licensing and are ensuring active partnership between Bharat Biotech and three other entities to enhance the production of Covaxin. A similar mechanism is being followed for Sputnik," he said.
He asked people to think about the fact that Moderna had said in October 2020 that it will not sue any company which makes its vaccines, but still, not one company has done it. He said that this shows licensing is the least of the issues. "If vaccine-making was so easy, why would even the developed world be so short of vaccine doses?" he asked.
Myth 5: Centre has abdicated its responsibility to the states
NiTi Aayog member said the Central Government is doing all the heavy-lifting, from funding vaccine manufacturers to giving them quick approvals to ramping up production to bringing foreign vaccines to India.
"The vaccine procured by the Centre is supplied wholly to the states for free administration to people. All this is very much in the knowledge of the states. GoI has merely enabled states to try procuring vaccines on their own, on their explicit requests. The states very well knew the production capacity in the country and what the difficulties are in procuring vaccines directly from abroad. In fact, GoI ran the entire vaccine program from January to April and it was quite well-administrated compared to the situation in May. But states, that had not even achieved good coverage of healthcare workers and frontline workers in three months wanted to open up the process of vaccination and wanted more decentralisation," he said.
Dr paul noted that health is a state subject and the liberalised vaccine policy was a result of the incessant requests being made by the states to give states more power. "The fact that global tenders have not given any results only reaffirms what we have been telling the states from day one that vaccines are in short supply in the world and it is not easy to procure them at short notice," he added.
Myth 6: Centre is not giving enough vaccines to the states
The Center is allotting enough vaccines to the states in a transparent manner as per agreed guidelines, informed Dr Paul.
"In fact, states are also being informed in advance of the vaccine availability. Vaccine availability is going to increase in near future and much more supply would be possible. In the non-GoI channel, states are getting 25 per cent of the doses and private hospitals are getting 25 per cent doses. However the hiccups and issues faced by the people in the administration of these 25 per cent doses by the states leave a lot to be desired," he said.
"The behaviour of some of our leaders, who in spite of full knowledge of the facts on vaccine supply, appear on TV daily and create panic among the people is very unfortunate. This is not the time to play politics. We need everyone to unite in this fight," NiTi Aayog member added.
Myth 7: Centre is not taking any step to vaccinate children
Dr Paul said as of now, no country in the world is giving vaccines to children and added that the WHO has no recommendation on vaccinating children.
"There have been studies about the safety of vaccines in children, which have been encouraging. Trials in children in India are also going to begin soon. However, vaccinating children should not be decided on the basis of panic in Whatsapp groups and because some politicians want to play politics. It has to be a decision taken by our scientists after adequate data is available based on trials," he said.